首页 › 心血管疾病 › 阿拉巴马州 › Huntsville
Huntsville AL 心血管疾病临床试验
8项针对 心血管疾病的研究正在 Huntsville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
招募中4 期
- Heart Center Research, LLC, Huntsville
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
招募中2 期
- Heart Center Research, LLC, Huntsville
Product Surveillance Registry
招募中观察性研究
- Huntsville, Huntsville
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
招募中3 期
- Clinical Trial Site, Huntsville
- Clinical Trial Site, Huntsville
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
招募中3 期
- Heart Center Research Llc, Huntsville
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
招募中3 期
- Research Site, Huntsville
- Research Site, Athens · 距离 22 英里
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
招募中3 期
- Heart Center Research LLC, Huntsville
Pivotal Study for the Cardiac Performance System (CPS)
招募中观察性研究
- Huntsville Hospital Heart Center, Huntsville
其他城市的 心血管疾病试验
- Boston, MA37 项研究
- New York City, NY33 项研究
- Washington, DC28 项研究
- Houston, TX24 项研究
- Dallas, TX23 项研究
- Atlanta, GA22 项研究
- Cleveland, OH22 项研究
- Chicago, IL21 项研究
- Philadelphia, PA21 项研究
- Pittsburgh, PA20 项研究
- St. Louis, MO20 项研究
- Nashville, TN18 项研究
Huntsville的其他研究
- 肥胖症7 项研究
- 冠状动脉疾病6 项研究
- 心力衰竭6 项研究
- 重度抑郁症6 项研究
- 2型糖尿病6 项研究
- 抑郁症6 项研究
- 动脉粥样硬化5 项研究
- 超重5 项研究
- 主动脉瓣狭窄4 项研究
- 慢性肾病4 项研究
- 心脏病发作3 项研究
- 癌症（所有类型）3 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。